186 related articles for article (PubMed ID: 36547689)
21. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
Kundu K; Ghosh S; Sarkar R; Edri A; Brusilovsky M; Gershoni-Yahalom O; Yossef R; Shemesh A; Soria JC; Lazar V; Joshua BZ; Campbell KS; Elkabets M; Porgador A
Cancer Immunol Res; 2019 Jul; 7(7):1120-1134. PubMed ID: 31164357
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
McWilliams EM; Mele JM; Cheney C; Timmerman EA; Fiazuddin F; Strattan EJ; Mo X; Byrd JC; Muthusamy N; Awan FT
Oncoimmunology; 2016; 5(10):e1226720. PubMed ID: 27853650
[TBL] [Abstract][Full Text] [Related]
24. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
25. NKG2A Expression Is Not
Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
Front Immunol; 2018; 9():1415. PubMed ID: 29988376
[TBL] [Abstract][Full Text] [Related]
26. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
[TBL] [Abstract][Full Text] [Related]
27. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
[TBL] [Abstract][Full Text] [Related]
28. Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells.
Hirabayashi H; Yasumura S; Lin WC; Amoscato A; Johnson JT; Herberman RB; Whiteside TL
Arch Otolaryngol Head Neck Surg; 1995 Mar; 121(3):285-92. PubMed ID: 7873144
[TBL] [Abstract][Full Text] [Related]
29. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
[TBL] [Abstract][Full Text] [Related]
30. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
[TBL] [Abstract][Full Text] [Related]
31. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans.
Bigley AB; Rezvani K; Shah N; Sekine T; Balneger N; Pistillo M; Agha N; Kunz H; O'Connor DP; Bollard CM; Simpson RJ
Clin Exp Immunol; 2016 Aug; 185(2):239-51. PubMed ID: 26940026
[TBL] [Abstract][Full Text] [Related]
32.
Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
[TBL] [Abstract][Full Text] [Related]
33. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
34. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
[TBL] [Abstract][Full Text] [Related]
35. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
37. Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors.
Hromadnikova I; Pirkova P; Sedlackova L
Mediators Inflamm; 2013; 2013():405295. PubMed ID: 23476104
[TBL] [Abstract][Full Text] [Related]
38. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
